Asset Details
Do you wish to reserve the book?
Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up
Do you wish to request the book?
Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up
2024
Overview
Background
To investigate the long-term effects of combining bone marrow mesenchymal stem cells (MSCs) with mononuclear cells (MCs) in the treatment of type 2 diabetes mellitus (T2DM).
Methods
T2DM patients were divided into the combination group (Dual MSC + MC,
n
= 33), the mononuclear cell group (MC-Only,
n
= 32) and the control group (Control,
n
= 31). All groups were treated with insulin and metformin. The Dual MSC + MC group additionally received MSC and MC infusion and the MC-Only group additionally received MC infusion. The patients were followed up for 8 years. The primary endpoint was the C-peptide area under the curve (C-p AUC) at 1 year. This study was registered with clinicaltrial.gov (NCT01719640).
Results
A total of 97 patients were included and 89 completed the follow-up. The area under the curve of C-peptide of the Dual MSC + MC group and the MC-Only group was significantly increased (50.6% and 32.8%, respectively) at 1 year. After eight years of follow-up, the incidence of macrovascular complications was 13.8% (
p
= 0.009) in the Dual MSC + MC group and 21.4% (
p
= 0.061) in the MC-Only group, while it was 44.8% in the Control group. The incidence of diabetic peripheral neuropathy (DPN) was 10.3% (
p
= 0.0015) in the Dual MSC + MC group, 17.9% (
p
= 0.015) in the MC-Only group, and 48.3% in the Control group.
Conclusions
The combination of MSC and MC therapy can reduce the incidence of chronic diabetes complications and improves metabolic control with mild side effects in T2DM patients.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Biomedical and Life Sciences
/ Biomedical Engineering and Bioengineering
/ Complications and side effects
/ Diabetes Mellitus, Type 2 - therapy
/ Ethylenediaminetetraacetic acid
/ Female
/ Humans
/ Insulin
/ Leukocytes, Mononuclear - metabolism
/ Male
/ Mesenchymal Stem Cell Transplantation - methods
/ Mesenchymal Stem Cells - cytology
/ Mesenchymal Stem Cells - metabolism
/ Peptides
